碘化油
癌症研究
肝细胞癌
转移
材料科学
纳米医学
生物物理学
医学
癌症
纳米技术
内科学
生物
纳米颗粒
作者
Xuqi Peng,Yating Zheng,Yi Xue,Xiaoliu Liang,Pan He,Hu Chen,Peng He,Yisheng Peng,Zhenwen Zhao,Yulun Chen,Xiran Gui,Lei Yang,Yongfu Xiong,Juan Lin,Yesi Shi,Chengchao Chu,Yang Zhang,Gang Liu
标识
DOI:10.1002/adfm.202311505
摘要
Abstract The clinical effectiveness of locoregional therapies in treating hepatocellular carcinoma (HCC) is frequently constrained by multi‐drug resistance and/or tumor metastasis. To surmount these challenges, a promising approach, transcatheter arterial ionic‐embolization (TAIE) is proposed, which can specifically and continuously disrupt the intracellular ionic balance to significantly inhibit tumor activity and invasion. The hydrophilic micro‐nanoscale sodium chloride particles (SCPs) are ingeniously intermixed with hydrophobic lipiodol to create a super‐stable homogeneous embolic formulation (lipiodol‐sodium chloride, LSC). After interventional administration, the LSC selectively deposits in HCC lesions, where lipiodol stably delivers SCPs to disrupt the cell's ionic balance, causing cell death without drug resistance. Notably, it is demonstrated that LSC can significantly hinder tumor cell migration and invasion. The mechanism is through SCP disruption of the ionic balance, which induces cell swelling and subsequent vimentin hydrolysis‐mediated cytoskeletal remodeling. In addition, it is found that LSC treatment notably downregulates the expression of MYLK, TLN, and THBS2 genes in the focal adhesion (FA) signaling pathway of HepG2 cells. LSC formulation integrated tumor‐specific deposition, intratumoral sustained release, efficient tumoricidal activity, significant metastasis inhibition, and excellent biological safety, thereby demonstrating superior in vivo tumor therapeutic effects via TAIE strategy, and showing a promising cancer therapeutic approach for clinical application.
科研通智能强力驱动
Strongly Powered by AbleSci AI